Status:

RECRUITING

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

Lead Sponsor:

Xueqin Yang

Conditions:

Evaluation

NSCLC

Eligibility:

All Genders

18+ years

Brief Summary

Investigators established the efficacy evaluation criteria for tumor markers (RecistTM) in the preliminary research. Among patients with advanced non-small cell lung cancer, patients with positive dri...

Detailed Description

Investigators established the efficacy evaluation criteria for tumor markers (RecistTM) in the preliminary research. The establishment of this criteria makes the application of tumor markers in clinic...

Eligibility Criteria

Inclusion

  • NSCLC patients with stage IIIB-IV
  • Driver gene positive (EGFR,ALK,C-MET, ROS,RET, HER2);
  • First line targeted therapy.
  • Performance status of 0-2 on the ECOG criteria.
  • Any one of the tumor markers is more than three times higher than the normal level, and the tumor markers include: CEA\>15ng/ml,CA-199\>105U/ml,CA-125\>105 U/ml, NSE\>60 ng/ml, SCCAg\>7.5 ng/ml, CYFRA21-1\>21 ng/ml, et al.
  • Measurable lesions present
  • Age\>=18
  • Adequate hematologic (neutrophil count \>= 1,500/uL, platelets \>= 60,000/uL,hemoglobin≥70g/L), hepatic (transaminase =\< upper normal limit(UNL)x2.5, bilirubin level =\< UNLx1.5), and renal (creatinine =\< UNL) function.
  • Informed consent from patient or patient's relative.

Exclusion

  • Patients with dysphagia;
  • Unable to taking medication on time;
  • Patients with a history of abuse of psychotropic substances who are unable to quit or have mental disorders

Key Trial Info

Start Date :

November 13 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2028

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT06142058

Start Date

November 13 2023

End Date

December 31 2028

Last Update

November 21 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cancer Center, Dapping Hospital, Army Medical Center of PLA

Chongqing, Chongqing Municipality, China, 400042

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC | DecenTrialz